Biogen Attacks Bass Group's AIA Review Bid For MS Drug
Biogen told the Patent Trial and Appeal Board on Friday to reject a bid by an organization with ties to hedge fund manager Kyle Bass to again consider instituting an America...To view the full article, register now.
Already a subscriber? Click here to view full article